Lexaria Bioscience (LEXX) Change in Accured Expenses (2014 - 2026)

Lexaria Bioscience has reported Change in Accured Expenses for 13 years, with the latest figure at $167768.0 in Q2 2026.

• Quarterly Change in Accured Expenses rose 150.11% year-over-year to $167768.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was -$1.1 million (down 183.33% YoY) and the FY2025 annual result came in at $396637.0, down 52.01% from the prior year.
• Change in Accured Expenses grew to $167768.0 in Q2 2026 per LEXX's latest filing, from -$1.2 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $1.5 million in Q1 2025 and troughed at -$1.2 million in Q1 2026.
• A 5-year average of $8935.3 and a median of -$21619.5 in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses tumbled 13829.01% in 2023, then jumped 3591.7% in 2025.
• Over 5 years, Change in Accured Expenses stood at $90442.0 in 2022, then tumbled by 255.87% to -$140973.0 in 2023, then slumped by 465.66% to -$797423.0 in 2024, then jumped by 95.28% to -$37613.0 in 2025, then surged by 546.04% to $167768.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $167768.0, -$1.2 million, and -$37613.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.